1. Use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced risk of developing substance use disorders among US veterans with type 2 diabetes.
Evidence Rating Level: 2 (Good)
Glucagon-like peptide-1 (GLP-1) receptor agonists have been associated with reduced risks of incident substance use disorders (SUDs) such as alcohol use and incident cannabis use disorder. However, the link between GLP-1 receptor agonists and risks of other SUDs, such as opioid use disorder and stimulant use disorder are unclear. This study thus investigated the relationship between initiation of GLP-1 receptor agonists and risk of incident SUDs across a range of substances in people with no history of SUDs. This cohort study emulated a set of eight parallel, new user target trials using the US Department of Veterans Affairs electronic health records and included veterans aged >18 and a diagnosis of type 2 diabetes. Participants were assigned to one of the two protocols: people without pre-existing SUD in protocol 1 and people with pre-existing SUD in protocol 2. For both protocols, treatment strategies of initiating a GLP-1 receptor agonist versus a sodium-glucose cotransporter-2 (SGLT-2) inhibitor were compared. Patients were followed for up to three years. The main outcomes of incident SUDs were alcohol, cannabis, cocaine, nicotine, opioid, other SUDs, and a composite of these outcomes. Out of the 524,817 participants included in Protocol 1, 124,001 initiated GLP-1 receptor agonists and or 400,816 initiated SGLT-2 inhibitors. Out of the 81,617 participants included in Protocol 2, 16,768 initiated GLP-1 receptor agonists, and 64,849 initiated SGLT-2 inhibitors. Compared with initiation of SGLT-2 inhibitors, initiation of GLP-1 receptor agonists was associated with 18% lower risk of alcohol use disorders (hazard ratio [HR], 0.8295%; 95% CI, 0.78 to 0.85), 14% lower risk of cannabis use (HR, 0.86; 95% CI, 0.81 to 0.90), 20% lower risk of cocaine use (HR, 0.80; 95% CI, 0.72 to 0.88), 20% lower risk of nicotine use (HR, 0.80; 95% CI, 0.74 to 0.87), 25% lower risk of opioid use (HR, 0.75; 95% CI, 0.67 to 0.85), 13% lower risk of other SUDs (HR, 0.87; 95% CI, 0.81 to 0.94), and 14% lower risk of composite outcome of all incident SUDs (HR, 0.86; 95% CI, 0.83 to 0.88). Overall, this study found that initiating GLP-1 receptor agonists was associated with reduced risk of developing various SUDs, highlighting its potential in the prevention of SUDs.
Click here to read this study in the BMJ (British Medical Journal)
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.







